Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 3:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 4,117 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Experimental 2 Clear all

Conditions: Communication Disorders
Interventions: Experimental AAC, Generic AAC; Device
Lead sponsor: Altec Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Natick, Massachusetts • Lincoln, Nebraska

Conditions: Cognitive Function
Interventions: olfactory enrichment (essential oils); Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 60 Years to 85 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Irvine, California

Conditions: Influenza
Interventions: Influsplit Tetra™ vaccine produced by investigational process (IP), Influsplit Tetra™ vaccine produced by licensed process (LP); Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Months to 49 Years
Enrollment: 1,886 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 4
States / cities: Wichita, Kansas • Rochester, New York • Warwick, Rhode Island + 1 more

Conditions: Hemorrhage, Soft Tissue Bleeding
Interventions: EVARREST™ Fibrin Sealant Patch, Standard of Care; Biological · Other
Lead sponsor: Ethicon, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Ovarian Cancer
Interventions: Pembrolizumab, Paclitaxel; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 3
States / cities: Tampa, Florida • Durham, North Carolina • Richmond, Virginia

Conditions: Anesthesia
Interventions: Negative Connotation Langauge, Positive Connotation Language; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Fibromyalgia, Pain, Functional Status, Self-Efficacy, Distress
Interventions: Relaxation and Guided Imagery; Behavioral
Lead sponsor: Florida International University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Malaria
Interventions: BNT165b1, Placebo; Biological · Other
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 5
States / cities: Tempe, Arizona • Baltimore, Maryland • Las Vegas, Nevada + 2 more

Conditions: Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
Interventions: KRT-232, acalabrutinib; Drug
Lead sponsor: Kartos Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Goshen, Indiana • Cincinnati, Ohio • Columbus, Ohio + 1 more

Conditions: Overweight , Obesity, Adults
Interventions: ALV-100, Placebo; Drug
Lead sponsor: Alveus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 20
States / cities: Birmingham, Alabama • Sun City, Arizona • Tempe, Arizona + 16 more

Conditions: Hepatic Encephalopathy
Interventions: Fecal Microbiota Transplant (FMT) oral capsules, Placebo oral capsule; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Invasive Aspergillosis, Invasive Pulmonary Aspergillosis
Interventions: Investigational Agent: VL-2397, Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B; Drug
Lead sponsor: Vical; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 11
States / cities: Birmingham, Alabama • La Jolla, California • Sacramento, California + 8 more

Conditions: Surgery
Interventions: Pre-oxygenation; Device
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Supratherapuetic dose of Nestorone, Placebo, Moxifloxacin; Drug
Lead sponsor: Population Council; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lymphocytic Leukemia
Interventions: NeoVax, Cyclophosphamide, Pembrolizumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections, HIV Metabolic Cardiovascular Syndrome, HIV Lipodystrophy, HIV Metabolic Syndromes, Hypertension
Interventions: Yoga lifestyle intervention, Standard of care; Behavioral · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Renal Transplant Rejection
Interventions: Sirolimus, Demographic Data, Medical History, and Donor Data, Blood Draws for Control Group, Blood Draws for Experimental Group, Donor Blood Draws, Donor Information, Kidney Biopsy; Drug · Other · Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Stroke, Hemiparesis
Interventions: Multichannel Functional electrical stimulation, Standard motor training; Device · Other
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Frisco, Texas

Conditions: Influenza
Interventions: Influenza A/H3N2 variant Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 211 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 4
States / cities: Decatur, Georgia • Iowa City, Iowa • Houston, Texas + 1 more

Conditions: HIV-Associated Cognitive Motor Complex, Aging, Cognitive Impairment, Cognitive Decline, Attention Impaired, Processing, Visual Spatial, Cognitive Deficit in Attention, Cognitive Disorder in Remission
Interventions: Individualized Cognitive Training, No-Contact Control; Behavioral · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 40 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: sigvotatug vedotin, docetaxel; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 762 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 130
States / cities: Anchorage, Alaska • Fullerton, California • Los Alamitos, California + 91 more

Conditions: Delayed Sleep Phase Syndrome
Interventions: Increase morning bright light, Decrease evening blue light, Sleep Scheduling, Monitor sleep, mood, and substance use; Other · Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 13 Years to 15 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cognitive Health, Mood
Interventions: Experimental, Placebo, Water; Dietary Supplement · Other
Lead sponsor: Nature's Sunshine Products, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Lehi, Utah

Conditions: Treatment Resistant Depression, MDD, Major Depressive Disorder, Recurrent Depression, Depression
Interventions: Psilocybin, Accelerated intermittent theta burst (aiTBS) rTMS treatment, Low-dose psilocybin, Sham Accelerated intermittent theta burst (aiTBS) rTMS treatment; Drug · Device
Lead sponsor: University of Texas at Austin; Other
Eligibility: 22 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Austin, Texas

Search by objective public record fields.

Adaptive and Individualized AAC

Sensory Enrichment for Older Adults

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and Children

EVARREST™ Fibrin Sealant Patch Post-Market Study

Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer

Poke and a Placebo

Pilot Study: Relaxation and Guided Imagery in Hispanic Persons Diagnosed With Fibromyalgia

Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

Fecal Microbiota Transplant as Treatment of Hepatic Encephalopathy

VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults

OPTiMASK: Comparison of Pre-oxygenation With Standard Face Mask Combined With High Flow Nasal Oxygen With Pre-oxygenation With Standard Face Mask Alone

A Study With an Open-Label Active Control to Evaluate the Potential of Nestorone® to Delay Cardiac Repolarization in Healthy Female Volunteers

A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.

Yoga for the Management of HIV-Metabolic Syndromes

Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients

Effectiveness of Multichannel Functional Electrical Stimulation

Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Adult and Elderly Populations

Individualized Cognitive Training in HIV

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

Experimental Manipulation of Sleep and Circadian Rhythms and the Role Played on Reward Function in Teens

Acute Cognitive Effects of Brain Edge

Psilocybin rTMS for Treatment Resistant Depression